Ernexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ERNA
Ernexa Therapeutics Inc. (ERNA) EV/Sales
As of 16 October 2026, Ernexa Therapeutics Inc. (ERNA) trades at a EV/Sales of 51.2×. Over the past ten years it has ranged from −0.8× (November 2022) to 1,168,652× (May 2015); the current reading is higher than 76% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 59.4× | 1,597.61% |
| FY2023 | 3.5× | (73.28%) |
| FY2020 | 13.1× | 4,090.91% |
| FY2020 | 0.3× | 1.46% |
| FY2019 | 0.3× | 1.75% |
| FY2019 | 0.3× | 0.43% |
| FY2018 | 0.3× | (55.45%) |
| FY2018 | 0.7× | 0.00% |
| FY2017 | 0.7× | (6.71%) |
| FY2017 | 0.7× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 59.4× | 5.26% |
| Sep 2024 | 56.4× | (45.65%) |
| Jun 2024 | 104× | 757.28% |
| Mar 2024 | 12.1× | 246.17% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | −3.3× |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| IOBTQ IO Biotech, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| UNBX UNITY Biotechnology, Inc. compare | n/m |
| KALA KALA BIO, Inc. compare | 7.5× |
| ERNA Ernexa Therapeutics Inc. | 51.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)